[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has Diamond-Blackfan anemia (due to RPS19 mutation) and has developed restrictive cardiomyopathy with pulmonary hypertension, likely related to chronic transfusions (iron overload) or possibly corticosteroid toxicity.  \n\nIn restrictive cardiomyopathy with severe diastolic dysfunction and secondary pulmonary hypertension, medical therapy (beta-blockers, ACE inhibitors) is often limited in benefit. Given the progressive symptoms and multiorgan involvement (anemia, iron overload, steroid effects), combined heart-lung transplantation may be considered for restrictive cardiomyopathy with severe pulmonary hypertension, especially if due to DBA complications and not reversible.  \n\nOption A is not best because high-dose beta-blockers/ACE inhibitors can be poorly tolerated in restrictive physiology.  \nOption C is incorrect because abruptly stopping corticosteroids could be dangerous if still needed for DBA, and defibrotide is not indicated here.  \nOption D (L-leucine) is experimental in DBA but not for established cardiomyopathy.  \nOption E (cardiac MRI) would be diagnostic but not the most appropriate next step in management given the severity; the patient likely needs advanced therapy evaluation.  \n\nThe most appropriate next step is referral for transplant evaluation given end-stage restrictive cardiomyopathy and pulmonary hypertension.  \n\nThe answer is B"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has severe features of preeclampsia with persistent severe hypertension despite first-line antihypertensives (labetalol and hydralazine).  \nNitroprusside is generally avoided in pregnancy unless absolutely necessary due to risk of cyanide toxicity in the fetus, and it is not first-line in this setting.  \nOral nifedipine XL can be used but is not the best next step for acute severe hypertension that is refractory to IV labetalol and hydralazine.  \nFenoldopam is a peripheral dopamine-1 agonist that lowers blood pressure and may preserve renal perfusion; it is an acceptable alternative in severe hypertension in pregnancy when first-line agents fail, and it avoids fetal cyanide risk.  \nSublingual captopril is contraindicated in pregnancy due to fetal renal toxicity.  \nEsmolol is a beta-blocker similar to labetalol; switching to another beta-blocker is less likely to add benefit after labetalol failure.  \n\nGiven the options, fenoldopam is the most appropriate next pharmacologic intervention for refractory severe hypertension in this pregnant patient with preeclampsia.  \n\nThe answer is C"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient has severe immune checkpoint inhibitor (ICI)-related pneumonitis that is steroid-refractory after 72 hours of high-dose methylprednisolone.  \nIn such cases, guidelines recommend adding a second-line immunosuppressive agent.  \nInfliximab (a TNF-alpha inhibitor) is often considered, but carries a risk of worsening pneumonitis and is generally avoided in pulmonary toxicity.  \nTocilizumab (an IL-6 receptor antagonist) has emerging evidence for steroid-refractory ICI pneumonitis and may be safer than infliximab for lung involvement.  \nPlasma exchange is not standard for ICI pneumonitis. Cyclophosphamide is more often used for other refractory immune toxicities (e.g., myocarditis) but not first-line for pneumonitis. Switching to dexamethasone is not an escalation in therapy.  \n\nGiven current evidence and expert recommendations, tocilizumab is increasingly used for steroid-refractory ICI pneumonitis.  \n\nThe answer is E"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The presentation (poor feeding, lethargy, hypoglycemia, macroglossia, umbilical hernia, hepatomegaly) is classic for **galactosemia**, specifically classic galactosemia due to galactose-1-phosphate uridyltransferase (GALT) deficiency.  \nNewborn screening already shows elevated galactose and galactitol, which supports this.  \n\n- **A** – Elevated ammonia can occur in galactosemia due to liver dysfunction, but it is not specific.  \n- **B** – In galactosemia, urine reducing substances are **present** (not absent) after lactose/galactose intake.  \n- **C** – Liver biopsy glycogen content is not a specific diagnostic test for galactosemia.  \n- **D** – Deficient GALT activity in erythrocytes is the definitive diagnostic test for classic galactosemia.  \n- **E** – Cataracts can occur due to galactitol accumulation, but they are not always present early and are not as specific as enzyme assay.  \n\nThe **most specific** for confirming diagnosis is the enzyme assay.  \n\nThe answer is D"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has antiphospholipid syndrome (APS) with acute thrombosis despite therapeutic warfarin (INR 2.5–3.5), which is already at the higher target range for APS.  \nRecurrent thrombosis on warfarin suggests **warfarin failure**, which in APS often requires a different approach.  \n\n- **A** – Rivaroxaban (a direct oral anticoagulant) is less effective than warfarin in high-risk APS (especially triple-positive APS) and is associated with higher recurrent thrombosis risk in this population.  \n- **B** – Increasing INR target beyond 3.5 increases bleeding risk without clear evidence of benefit in APS.  \n- **C** – Hydroxychloroquine has immunomodulatory and antithrombotic effects in APS and lupus, and adding it to anticoagulation is recommended in refractory or recurrent APS thrombosis.  \n- **D** – IVIG is used in certain refractory autoimmune cases but is not first-line for APS thrombosis on warfarin.  \n- **E** – IVC filter is for contraindication to anticoagulation, not for anticoagulation failure.  \n\nThe most appropriate next step is to add hydroxychloroquine while maintaining therapeutic anticoagulation.  \n\nThe answer is (C)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let’s break this down:  \n\n- Patient has **ischemic cardiomyopathy, LVEF 25%**, already on guideline-directed medical therapy (beta-blocker, ACEi, MRA).  \n- He has a **CRT-D** and is getting recurrent appropriate shocks for VT.  \n- Amiodarone was tried but stopped due to thyroid toxicity.  \n- Need to choose the **next antiarrhythmic** that is safe and effective in low LVEF, ischemic cardiomyopathy.  \n\n**Option A: Mexiletine** – Often used in combination with amiodarone; as monotherapy, less effective for VT in structural heart disease. Not first-line here.  \n\n**Option B: Sotalol** – **Contraindicated** in LVEF < 30–35% per major trials (SWORD) due to increased mortality in ischemic cardiomyopathy with low EF. Also, non-selective beta-blocker, but he’s already on carvedilol; risk of torsades.  \n\n**Option C: Dofetilide** – Requires inpatient initiation and monitoring, but **safe in low LVEF** (used in CHF patients in DIAMOND trials). Effective for atrial and ventricular arrhythmias, no negative inotropy. Appropriate here.  \n\n**Option D: Ranolazine** – Anti-anginal with antiarrhythmic properties, but not FDA-approved as primary antiarrhythmic for VT, and evidence for reducing shocks is less robust.  \n\n**Option E: Propafenone** – **Contraindicated** in structural heart disease (especially ischemic cardiomyopathy) due to increased mortality (CAST trial logic applies to class IC drugs).  \n\nGiven the above, **dofetilide** is the only one that is both safe in low LVEF ischemic cardiomyopathy and effective for VT, with a requirement for monitored initiation.  \n\n**The answer is (C)**"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Peripartum cardiomyopathy with LVEF 30% is a form of heart failure with reduced ejection fraction (HFrEF).  \nStandard HFrEF medications include beta-blockers (like metoprolol), ACE inhibitors/ARBs, ARNI (sacubitril/valsartan), diuretics, and sometimes digoxin or hydralazine/nitrates.  \n\nHowever, in pregnancy, certain drugs are contraindicated due to fetal risk:  \n- **ACE inhibitors, ARBs, and ARNI (sacubitril/valsartan)** are contraindicated in pregnancy (especially second and third trimesters) due to risks of fetal renal damage, oligohydramnios, lung hypoplasia, and fetal death.  \n- Hydralazine and nitrates are often used as afterload reducers in pregnancy when ACE/ARB cannot be used.  \n- Beta-blockers (like metoprolol) can be used cautiously.  \n- Digoxin is generally considered safe in pregnancy.  \n\nSince the patient is still pregnant (36 weeks), sacubitril/valsartan (an ARNI) should be avoided until after delivery.  \n\nThe answer is (D)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient has sinopulmonary infections, low IgA/IgM with low-normal IgG, absent B cells, plus cerebellar ataxia and nystagmus with cerebellar atrophy on MRI.  \n\nThis combination points to **ataxia-telangiectasia**, which is caused by mutation in the **ATM gene**.  \nIt involves cerebellar degeneration (ataxia, nystagmus), immunodeficiency (low IgA/IgM, absent B cells possible in later stages), recurrent infections, and telangiectasias (though not mentioned in question).  \n\n- BTK (A) → X-linked agammaglobulinemia: absent B cells, but no cerebellar ataxia.  \n- CD40 ligand deficiency (B) → Hyper-IgM syndrome, ataxia not typical.  \n- AICDA deficiency (C) → Hyper-IgM syndrome type 2, no ataxia.  \n- RAG1 (D) → SCID or Omenn syndrome, no cerebellar atrophy.  \n- ATM (E) → matches cerebellar ataxia with immunodeficiency.  \n\nThe answer is E"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "In refractory hepatic encephalopathy with contraindications to TIPS, the intervention with the strongest evidence for reducing recurrence is **oral L-ornithine L-aspartate (LOLA)**, which enhances ammonia detoxification via the urea and glutamine synthesis pathways.  \nMultiple randomized controlled trials and meta-analyses support its efficacy in reducing ammonia and improving encephalopathy when added to standard therapy.  \n\nThe answer is C"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Trastuzumab-induced cardiotoxicity is typically reversible and not associated with significant cardiomyocyte necrosis, so troponin levels are often normal or only mildly elevated, while NT-proBNP is elevated due to stress and volume overload.  \nAnthracycline-induced cardiotoxicity involves oxidative stress and direct myocardial damage, leading to elevated troponin and often more severe, irreversible injury.  \nElevated NT-proBNP with normal troponin is more characteristic of trastuzumab-induced cardiomyopathy, whereas anthracycline toxicity often shows both markers elevated.  \n\nThe answer is B"}]